Related Experiment Video
Updated: Oct 12, 2025
A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
Antibiotic Treatment, Mechanisms for Failure, and Adjunctive Therapies for Infections by Group A Streptococcus
Anders F Johnson1, Christopher N LaRock1,2,3,4
1Microbiology and Molecular Genetics Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA, United States.
Abstract:
Group A Streptococcus (GAS; Streptococcus pyogenes) is a nearly ubiquitous human pathogen responsible for a significant global disease burden. No vaccine exists, so antibiotics are essential for effective treatment. Despite a lower incidence of antimicrobial resistance than many pathogens, GAS is still a top 10 cause of death due to infections worldwide. The morbidity and mortality are primarily a consequence of the immune sequelae and invasive infections that are difficult to treat with antibiotics. GAS has remained susceptible to penicillin and other β-lactams, despite their widespread use for 80 years. However, the failure of treatment for invasive infections with penicillin has been consistently reported since the introduction of antibiotics, and strains with reduced susceptibility to β-lactams have emerged. Furthermore, isolates responsible for outbreaks of severe infections are increasingly resistant to other antibiotics of choice, such as clindamycin and macrolides. This review focuses on the challenges in the treatment of GAS infection, the mechanisms that contribute to antibiotic failure, and adjunctive therapeutics. Further understanding of these processes will be necessary for improving the treatment of high-risk GAS infections and surveillance for non-susceptible or resistant isolates. These insights will also help guide treatments against other leading pathogens for which conventional antibiotic strategies are increasingly failing.
Insights
Group A Streptococcus (GAS) infections pose a global health threat due to antibiotic treatment challenges. Understanding resistance mechanisms is crucial for improving outcomes and developing new therapies against this pathogen.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Group A Streptococcus (GAS), or Streptococcus pyogenes, is a widespread pathogen causing significant global morbidity and mortality.
- Despite GAS remaining largely susceptible to penicillin, treatment failures for invasive infections are common, and resistance to alternative antibiotics like clindamycin and macrolides is increasing.
- No vaccine is currently available, making antibiotics the cornerstone of GAS infection management.
Purpose of the Study:
- To review the challenges associated with treating GAS infections.
- To explore the mechanisms underlying antibiotic treatment failures in GAS.
- To discuss the role of adjunctive therapeutics in managing high-risk GAS infections.
Main Methods:
- Literature review focusing on antibiotic resistance, treatment outcomes, and therapeutic strategies for GAS infections.
- Analysis of emerging resistance patterns and mechanisms of antibiotic tolerance in Streptococcus pyogenes.
- Examination of clinical data and research on adjunctive therapies for invasive GAS disease.
Main Results:
- While GAS remains susceptible to penicillin, increasing reports of treatment failures for invasive infections exist.
- Emergence of GAS isolates with reduced susceptibility or resistance to alternative antibiotics like clindamycin and macrolides is a growing concern.
- Immune sequelae and invasive infections contribute significantly to GAS-related mortality, often proving difficult to treat with conventional antibiotics.
Conclusions:
- Improved understanding of GAS antibiotic resistance and treatment failure mechanisms is essential for clinical practice.
- Enhanced surveillance for non-susceptible and resistant GAS strains is necessary.
- Developing novel therapeutic strategies and adjunctive treatments is critical for combating severe GAS infections and informing treatments for other challenging pathogens.
More Related Videos
09:25Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells
Published on: August 19, 2016
11:15Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:21Rheumatic Heart Disease III: Medical Management
01:26Mitral Stenosis III: Medical Management
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:30Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause: